Radau G, Fokkens J
Institute of Pharmacy, Ernst-Moritz-Arndt-University Greifswald, Germany.
Pharmazie. 2007 Feb;62(2):83-8.
Based on the X-ray crystals of cocrystallized cyanopeptide-trypsin and cyanopeptide-thrombin-com-plexes, a rational drug design succeeded in the establishment of suitable lead structures for the development of new potential inhibitors of thrombin. This report deals with the design and X-ray crystallography data of new synthetic, low-molecular weight cyanopeptide-analogues, RA-1008 and RA-1014, complexed with human alpha-thrombin at 1.85 A resolution. The crystal structures of the complexes reveal, by analogy with modeling studies, that the salt bridge of Asp189 to this type of synthetic thrombin inhibitors leads to an almost identically binding into the S1 specificity pocket in comparison to the complex of the natural products, whereas in the overall binding modes the P2-P4 substructures differ from those of the leads. The strongest member of the second series of described thrombin inhibitors, RA-1014, shows in the crystal complex with thrombin a slightly higher affinity towards the enzyme than RA-1008 as confirmed by inhibition tests. This result and other key informations will be helpful to design a more potent series of inhibitors.
基于共结晶氰肽 - 胰蛋白酶和氰肽 - 凝血酶复合物的X射线晶体,合理药物设计成功建立了适合开发新型潜在凝血酶抑制剂的先导结构。本报告涉及新型合成低分子量氰肽类似物RA - 1008和RA - 1014与人类α - 凝血酶在1.85 Å分辨率下复合的设计及X射线晶体学数据。复合物的晶体结构通过与建模研究类比表明,与天然产物复合物相比,Asp189与这类合成凝血酶抑制剂形成的盐桥导致其几乎以相同方式结合到S1特异性口袋中,而在整体结合模式上,P2 - P4亚结构与先导物不同。所描述的第二代凝血酶抑制剂中最强的成员RA - 1014,在与凝血酶的晶体复合物中显示出比对RA - 1008对该酶稍高的亲和力,抑制试验证实了这一点。这一结果和其他关键信息将有助于设计出更有效的抑制剂系列。